Enfusion (NYSE:ENFN) Price Target Lowered to $11.00 at Morgan Stanley

Posted by Defense World Staff on Aug 13th, 2023

Enfusion (NYSE:ENFN – Free Report) had its price target decreased by Morgan Stanley from $12.00 to $11.00 in a research note published on Wednesday morning, Benzinga reports. Morgan Stanley currently has an overweight rating on the stock.

A number of other equities research analysts also recently issued reports on the stock. The Goldman Sachs Group reduced their price target on shares of Enfusion from $11.50 to $10.00 and set a neutral rating for the company in a research report on Wednesday. Piper Sandler dropped their price objective on shares of Enfusion from $11.00 to $9.00 in a research note on Monday, May 22nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of Hold and a consensus target price of $11.00.

Check Out Our Latest Stock Analysis on ENFN

Enfusion Stock Up 2.0 %

Shares of NYSE:ENFN opened at $8.18 on Wednesday. The company has a market cap of $951.25 million, a P/E ratio of 102.26, a PEG ratio of 1.31 and a beta of 0.83. Enfusion has a 52 week low of $7.37 and a 52 week high of $15.45. The company has a 50-day moving average price of $10.08 and a 200 day moving average price of $9.93.

Insider Buying and Selling at Enfusion

In related news, CTO Dan Groman sold 3,877 shares of Enfusion stock in a transaction on Tuesday, June 20th. The shares were sold at an average price of $8.86, for a total transaction of $34,350.22. Following the transaction, the chief technology officer now owns 112,718 shares in the company, valued at approximately $998,681.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CTO Dan Groman sold 3,877 shares of Enfusion stock in a transaction on Tuesday, June 20th. The shares were sold at an average price of $8.86, for a total transaction of $34,350.22. Following the transaction, the chief technology officer now owns 112,718 shares in the company, valued at approximately $998,681.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Tarek Hammoud sold 1,000,000 shares of the business’s stock in a transaction on Tuesday, July 11th. The stock was sold at an average price of $10.70, for a total transaction of $10,700,000.00. Following the completion of the transaction, the insider now owns 386 shares in the company, valued at approximately $4,130.20. The disclosure for this sale can be found here. Insiders have sold a total of 1,010,126 shares of company stock worth $10,797,934 in the last quarter. 39.18% of the stock is owned by insiders.

Institutional Investors Weigh In On Enfusion

Several hedge funds and other institutional investors have recently modified their holdings of the stock. New York State Common Retirement Fund grew its position in Enfusion by 78.8% in the 1st quarter. New York State Common Retirement Fund now owns 1,210,171 shares of the company’s stock worth $12,707,000 after purchasing an additional 533,198 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of Enfusion during the first quarter valued at approximately $270,000. Acadian Asset Management LLC increased its stake in Enfusion by 349.3% in the 1st quarter. Acadian Asset Management LLC now owns 107,412 shares of the company’s stock valued at $1,125,000 after buying an additional 83,506 shares during the period. Tower Research Capital LLC TRC lifted its position in Enfusion by 95.3% in the 1st quarter. Tower Research Capital LLC TRC now owns 12,782 shares of the company’s stock worth $135,000 after buying an additional 6,237 shares in the last quarter. Finally, New York Life Investment Management LLC purchased a new stake in Enfusion in the 1st quarter worth approximately $484,000. Institutional investors own 39.63% of the company’s stock.

About Enfusion

(Get Free Report)

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.